Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JNJ

Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program

Johnson Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in rheumatoid arthritis (RA) patients with refractory disease.

How Is Johnson & Johnson’s Stock Performance Compared to Other Healthcare Stocks?

How Is Johnson & Johnson’s Stock Performance Compared to Other Healthcare Stocks?

Johnson & Johnson has significantly outperformed other healthcare stocks over the past year, and analysts remain moderately bullish on the stock’s prospects.

3 Dividend Growth Leaders to Buy Now

3 Dividend Growth Leaders to Buy Now

Procter & Gamble, PepsiCo, and Johnson & Johnson stand out as dividend growth leaders with upside potential into year-end

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

JNJ Stock Surge Signals Confidence in New Growth Path

Johnson & Johnson's strategic shift to a focused pharma and medtech model is fueling growth through a powerful drug pipeline and key acquisitions.

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

3 Big Dividend Plays With Strong Earnings to Back Them

Three major dividend names—Waste Management, Eversource, and Johnson & Johnson—each gave investors new reasons to keep them in mind thanks to recent earnings.

Worried About a Fading Rally? Consider These 3 Dividend Stocks

Volatility is back in the markets, and jobs data points to a weakening labor market. Is it time to get defensive? Consider these 3 dividend stocks for income.

inkl

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson Stock: Analyst Estimates & Ratings

Johnson & Johnson Stock: Analyst Estimates & Ratings

Johnson & Johnson has outpaced the broader market and the healthcare sector in 2025, and analysts remain optimistic about the stock’s prospects.

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise

4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise

With solid Q2 results and 2025 guidance increases, Wall Street is upgrading these four stocks. Analysts now see palpable upside in one streaming stalwart.

Want Steady Income? 3 Top Dividend Stocks for July 2025

Want Steady Income? 3 Top Dividend Stocks for July 2025

Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Shares of Johnson Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report.

Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings

Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings

Johnson Johnson (NYSE:JNJ) posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.

Get all your
news in one place.

100's of premium titles.
One news app.

Johnson & Johnson Credits Tariff Delays For Strong Earnings, While Jim Cramer Pegs It On 'Lower Than Thought' Levies

Johnson Johnson (NYSE:JNJ) delivered better-than-expected second quarter results, with the management hinting at leveraging tariff delays to maintain its outlook; however, CNBC’s Jim Cramer credited the performance to lower tariffs.

JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now

Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.

Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson Johnson (NYSE:JNJ) will release earnings results for the second quarter, before the opening bell on Wednesday, July 16.

Get all your
news in one place.

100's of premium titles.
One news app.

Here's What to Expect From Johnson & Johnson's Next Earnings Report

Johnson & Johnson is set to unveil its Q2 results in the upcoming month, and analysts expect its profitability to observe a notable decline.

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

Why This Statistical Edge Favors CRWD, JNJ and LULU For the Coming Week

While narratives provide interesting context and color, empirical data delivers a quantitative advantage for astute options traders.

3 Top Dividend Stocks Analysts Are Bullish on Right Now

With earnings season coming to an end, investors are looking for new catalysts; here are three blue-chip companies with strong analyst support

Johnson & Johnson Stock: Is JNJ Outperforming the Healthcare Sector?

Johnson & Johnson has outpaced the broader healthcare sector over the past year, and analysts remain optimistic about the stock’s prospects.

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market

For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider

1 2 3 4 5

People

196,400 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Rheumatoid Arthritis

Places

386,192 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play